Group 1 - The core viewpoint of the article is the strategic partnership between Baiyang Pharmaceutical and Peking University International Hospital to establish a precision radiotherapy center focused on brain tumor treatment [1] - The center will utilize the ZAP-X robotic radiosurgery system operated by Baiyang Pharmaceutical to enhance the precision of brain tumor radiotherapy [1] - The collaboration aims to create a specialized treatment platform for brain tumors, optimizing the radiotherapy experience [1]

Core Viewpoint - The company has signed a cooperation agreement with Peking University International Hospital to establish and operate a radiosurgery treatment center, enhancing the accessibility of quality medical resources [1] Group 1: Agreement Details - The cooperation agreement was signed on October 23, 2025, and has a duration of eight years from the date of signing [1] - The agreement includes clear provisions regarding termination and exit mechanisms, liability for breach, and dispute resolution [1] Group 2: Impact on Company - This collaboration is expected to improve the company's sustainable profitability and have a positive impact on its performance [1]

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号： | 2025-089 | | --- | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | | 二、交易合作方介绍 （一）基本情况 单位名称：北京大学国际医院 法定代表人：梁军 开办资金：15,000 万人民币 青岛百洋医药股份有限公司 关于签署合作协议的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次协议签署概况 为推动高端放疗设备临床落地、提高优质医疗资源可及性，发挥双方的资源 优势，青岛百洋医药股份有限公司（以下简称"公司""百洋医药"）与北京大学 国际医院（以下简称"北大国际医院"）于 2025 年 10 月 23 日在北京市签署了《放 射外科治疗中心合作协议》，约定双方通过资源互补、优势协同的方式开展合作， 共同建设并运营放射外科治疗中心，并对双方合作方式等权利义务作出明确约定。 本次签署协议审批权限在总经理权限范围内，公司已履行了签署本协议的内 部审批程序，无需公司董事会及股东会审议批准。 住所：北京市昌平区 ...

Core Insights - The pharmaceutical commercial sector saw an increase of 0.83% on October 22, with Jianfa Zhixin leading the gains [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Stock Performance - Jianfa Zhixin (301584) closed at 31.00, up 7.19% with a trading volume of 238,100 shares and a transaction value of 734 million [1] - Guoyao Shares (600511) closed at 29.89, up 3.75% with a trading volume of 180,500 shares and a transaction value of 539 million [1] - Zhejiang Nongyuan (000705) closed at 9.81, up 3.05% with a trading volume of 117,170 shares and a transaction value of 168 million [1] - Other notable stocks include Jiashitang (002462) up 1.51%, Daclin (603233) up 1.34%, and Guofa Shares (600538) up 1.20% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 98.42 million from institutional investors and 51.45 million from retail investors, while individual investors saw a net inflow of 150 million [2] - The capital flow for key stocks shows varying trends, with Shanghai Pharmaceuticals (601607) seeing a net inflow of 31.94 million from institutional investors [3] - Jianfa Zhixin (301584) had a net inflow of 18.64 million from institutional investors but a net outflow of 2.07 million from retail investors [3]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.77% on October 17, with Baiyang Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3839.76, down 1.95%, while the Shenzhen Component Index closed at 12688.94, down 3.04% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed mixed performance, with Jianfa Zhixin rising by 4.20% to a closing price of 28.05, while Baiyang Pharmaceutical fell by 3.09% to 25.75 [1][2] - Other notable performers included Yifeng Pharmacy (+1.19%), Dacilin (+1.10%), and Dajia Weikang (+0.35%) [1][2] Trading Volume and Value - Jianfa Zhixin had a trading volume of 194,100 shares and a transaction value of 547.1 million yuan, while Baiyang Pharmaceutical had a trading volume of 33,700 shares and a transaction value of 118.76 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 246 million yuan from institutional investors, while retail investors contributed a net inflow of 220 million yuan [2][3] - Notable capital flows included Jianfa Zhixin with a net inflow of 44.84 million yuan from institutional investors, while Baiyang Pharmaceutical experienced a net outflow of 964,800 yuan [3]

Group 1 - The 67th American Society for Radiation Oncology (ASTRO) annual meeting showcased ZAP Surgical's ZAP-X, a cutting-edge brain tumor precision radiotherapy robot, highlighting its technological breakthroughs and clinical results [1] - A peer-reviewed scientific study presented at the conference revealed significant differences in low-dose radiation spillover to healthy brain tissue across different platforms, with a maximum difference of up to 50 times [1] - ZAP-X demonstrated superior protection of healthy brain tissue compared to traditional radiotherapy devices, and it offers a 20% reduction in treatment time compared to specialized cranial radiotherapy equipment, enhancing treatment quality for patients with brain metastases [1] Group 2 - Despite advancements in stereotactic radiosurgery (SRS), nearly 80% of patients still lack access to high-quality treatment due to cost, facilities, and technical issues, particularly for benign and malignant brain tumors [2] - ZAP-X is designed to optimize brain precision radiotherapy using a pioneering dual-rotating spherical structure, achieving higher target doses while minimizing exposure to surrounding healthy tissue [2] - The system's innovations include sub-millimeter precision, real-time dose imaging, and ultra-low leakage from the collimator, setting a new benchmark in precision and safety for global radiosurgery [2] Group 3 - ZAP-X has received market approval in 24 countries and regions, with over 70 global clients and more than 5,000 clinical treatments completed [3] - The company is actively promoting the clinical implementation and global manufacturing of ZAP-X in China, with a high-end manufacturing base in Beijing set to become the global production supply center [3] - The company has established a comprehensive disease scenario layout in precision radiotherapy, covering brain, body, and cardiac treatments, and aims to drive the global deployment of top-tier radiotherapy technology through innovation and localized manufacturing [3]

（编辑 任世碧） 证券日报网讯 10月15日晚间，百洋医药发布公告称，公司于2025年8月27日召开第三届董事会第三十三 次会议，并于2025年9月17日召开2025年第三次临时股东大会，审议通过了《关于变更注册资本并修订 的议案》。近日，公司完成了相关工商变更登记手续，并取得了青岛市行政审批服务局换发的《营业执 照》。 ...

证券日报网讯 10月15日晚间，百洋医药发布公告称，东兴证券作为公司2021年度首次公开发行股票并 在创业板上市项目（简称"上市项目"）和2023年度向不特定对象发行可转换公司债券项目（简称"可转 债项目"）的持续督导保荐机构，目前正在履行持续督导职责。东兴证券委派张羽中先生、周磊先生作 为公司保荐代表人，负责上述项目的持续督导工作，上述项目持续督导期限至募集资金使用完毕为止， 可转债项目持续督导期至2025年12月31日为止。因东兴证券原委派保荐代表人张羽中先生、周磊先生工 作变动，不再负责对公司的持续督导工作。为保证持续督导工作的有序进行，东兴证券现委派保荐代表 人朱海洲先生、姚维先生继续履行对公司持续督导的相关职责和义务。 （编辑 任世碧） ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-088 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 因东兴证券原委派保荐代表人张羽中先生、周磊先生工作变动，不再负责对公 司的持续督导工作。为保证持续督导工作的有序进行，东兴证券现委派保荐代表人 朱海洲先生、姚维先生（简历见附件）继续履行对公司持续督导的相关职责和义务。 青岛百洋医药股份有限公司 关于变更持续督导保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 青岛百洋医药股份有限公司（以下简称"公司"）于近日收到保荐机构东兴证 券股份有限公司（以下简称"东兴证券"）出具的《关于更换持续督导保荐代表人 的函》。 东兴证券作为公司 2021 年度首次公开发行股票并在创业板上市项目（以下简称 "上市项目"）和 2023 年度向不特定对象发行可转换公司债券项目（以下简称"可 转债项目"）的持续督导保荐机构，目前正在履行持续督导职责。东兴证券委派张 羽中先生、周磊先生作为公司保荐代表人，负责上述项目的持续督导工作，上市 ...

| 证券代码：301015 | 证券简称：百洋医药 | 公告编号：2025-087 | | --- | --- | --- | | 债券代码：123194 | 债券简称：百洋转债 | | 青岛百洋医药股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 统一社会信用代码：91370200770281005N 类型：其他股份有限公司（上市） 住所：山东省青岛市市北区桐柏路 88 号 1 号楼 法定代表人：付钢 注册资本：伍亿贰仟伍佰陆拾壹万玖仟伍佰壹拾伍元整 青岛百洋医药股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开 第三届董事会第三十三次会议，并于 2025 年 9 月 17 日召开 2025 年第三次临时 股东大会，审议通过了《关于变更注册资本并修订<公司章程>的议案》，具体内 容详见公司于 2025 年 8 月 29 日在巨潮资讯网（www.cninfo.com.cn）披露的《青 岛百洋医药股份有限公司关于变更注册资本并修订<公司章程>及制定、修订、 废止相关管理制度的公告》。 近日 ...